Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › VENTURE-Oral (phase 2)

VENTURE-Oral (phase 2)

VK2735 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
VK2735
Population
obesity
Phase
2
Participants
40
Duration
13 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
oral VK2735 90 mg dailyobesity1340——−11.1 % vs −1.3 %
estimand not specified
——25.0 vs 18.0————verified
oral VK2735 120 mg dailyobesity1340——−12.2 % vs −1.3 %
estimand not specified
——38.0 vs 18.0————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (4)
  • oral VK2735 90 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
    Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
  • oral VK2735 90 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
    Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
  • oral VK2735 120 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
    Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
  • oral VK2735 120 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
    Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: VENTURE-Oral (phase 2). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture-oral/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.